In a phase I/II trial (NCT03491683, https://clinicaltrials.gov/study/NCT03491683, accessed on 27 October 2024) [105], a DNA vaccine containing INO-5401, a synthetic DNA plasmid encoding human TERT, Wilms Tumor gene-1 (WT-1) and prostate-specific membrane antigen (PSMA) plus INO-9012 a synthetic DNA plasmid encoding IL-12, in combination with cemiplimab, a PD-1 inhibitor, was evaluated in two glioblastoma cohorts (A: unmethylated MGMT; B: methylated MGMT). The gene discussed is MGMT; the disease is glioblastoma.